Toxic myopathies

Neurologic Clinics

Volumn 32, Issue 3, 2014, Pages 647-670

  Pasnoor, Mamatha ^a   Barohn, Richard J ^a   Dimachkie, Mazen M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Muscle tissue; Myopathy; Statins; Toxic myopathies

Indexed keywords

ALCOHOL; ALPHA INTERFERON; AMIODARONE; AMPHOTERICIN; CHLOROQUINE; CIMETIDINE; CORTICOSTEROID; CYCLOSPORIN; DIURETIC AGENT; EMETINE; FIBRIC ACID DERIVATIVE; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; HYPOCHOLESTEROLEMIC AGENT; IMATINIB; LABETALOL; LAMOTRIGINE; LAXATIVE; NEUROMUSCULAR BLOCKING AGENT; OMEPRAZOLE; PENICILLAMINE; PHENYTOIN; PROPOFOL; TACROLIMUS; TOLUENE; TRYPTOPHAN; UNINDEXED DRUG; VINCRISTINE; ZIDOVUDINE; CREATINE KINASE; IMMUNOSUPPRESSIVE AGENT; TOXIN;

ALCOHOL ABUSE; CLINICAL FEATURE; ELECTROPHYSIOLOGY; GLYCYRRHIZA; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MUSCLE CELL; MUSCLE TISSUE; MYOPATHY; NECROTIZING MYOPATHY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TOXIC MYOPATHY; BLOOD; CHEMICALLY INDUCED; FEMALE; MALE; MUSCULAR DISEASES;

ANTICHOLESTEREMIC AGENTS; CREATINE KINASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MUSCULAR DISEASES; PROPOFOL; TOXINS, BIOLOGICAL;

EID: 84904284366     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2014.04.009     Document Type: Review

References (125)

1. Dalakas M.C. Toxic and drug-induced myopathies. JNeurol Neurosurg Psychiatry 2009, 80(8):832-838.
2. Kuncl R.W. Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009, 22(5):506-515.
3. Mammen A.L. Toxic myopathies. Continuum (Minneap Minn) 2013, 19(6 Muscle Disease):1634-1649.
4. Amato A.A., Rusell J.A. Neuromuscular disorders. Toxic myopathies. Chapter 32 2008, 737-761. McGraw Hill Companies Inc, New York. A.A. Amato, J.A. Russell (Eds.).
5. Argov Z., Mastaglia F.L. Drug-induced neuromuscular disorders in man. Disorders of voluntary muscle 1994, 989-1029. Churchill-Livingstone, Edinburgh (United Kingdom). 6th edition.
6. Needham M., Mastaglia F.L. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014, 24(1):4-15.
7. El-Salem K., Ababneh B., Rudnicki S., et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 2011, 44(6):877-881.
8. Greenberg S.A., Amato A.A. Statin myopathies. Continuum 2006, 12(3):169-184.
9. Mohassel P., Mammen A.L. The spectrum of statin myopathy. Curr Opin Rheumatol 2013, 25(6):747-752.
10. Walsh R.J., Amato A.A. Toxic myopathies. Neurol Clin 2005, 23(2):397-428.
11. Franc S., Dejager S., Bruckert E., et al. Acomprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003, 17(5-6):459-465.
12. Sakaeda T., Kadoyama K., Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One 2011, 6(12):e28124. 10.1371/journal.pone.0028124.
13. Muzyka I., Barohn R.J., Dimachkie M., et al. Necrotizing autoimmune statin-associated myopathy. JClin Neuromuscul Dis 2011, 12(3):17.
14. Phillips P.S., Haas R.H., Bannykh S., Scripps Mercy Clinical Research Center, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137(7):581-585.
15. Needham M., Fabian V., Knezevic W., et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007, 17(2):194-200.
16. Mammen A.L., Pak K., Williams E.K., et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012, 64(2):269-272.
17. Grable-Esposito P., Katzberg H.D., Greenberg S.A., et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41(2):185-190. 10.1002/mus.21486.
18. Mammen A.L., Chung T., Christopher-Stine L., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011, 63(3):713-721. 10.1002/art.30156.
19. Werner J.L., Christopher-Stine L., Ghazarian S.R., et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012, 64(12):4087-4093.
20. Slim H., Thompson P.D. Ezetimibe-related myopathy: a systematic review. JClin Lipidol 2008, 2(5):328-334.
21. Alsheikh-Ali A.A., Kuvin J.T., Karas R.H. Risk of adverse events with fibrates. Am J Cardiol 2004, 94(7):935-938.
22. Noppen M., Velkeniers B., Dierckx R., et al. Cyclosporine and myopathy. Ann Intern Med 1987, 107:945-946.
23. Atkison P., Joubert G., Barron A., et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995, 345(8954):894-896.
24. Breil M., Chariot P. Muscle disorders associated with cyclosporine treatment. Muscle Nerve 1999, 22(12):1631-1636.
25. Teicher A., Rosenthal T., Kissin E., et al. Labetalol-induced toxic myopathy. Br Med J (Clin Res Ed) 1981, 282(6279):1824-1825.
26. Willis J.K., Tilton A.H., Harkin J.C., et al. Reversible myopathy due to labetalol. Pediatr Neurol 1990, 6(4):275-276.
27. Short T.G., Young Y. Toxicity of intravenous anaesthetics. Best Pract Res Clin Anaesthesiol 2003, 17(1):77-89.
28. Hanson P., Dive A., Brucher J.M., et al. Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 1997, 20(11):1371-1380.
29. Francis L., Bonilla E., Soforo E., et al. Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol 2008, 27(1):129-131.
30. Strickland R.A., Murray M.J. Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship?. Crit Care Med 1995, 23(2):405-409.
31. Harris J.B., Scott-Davey T. Secreted phospholipases A2 of snake venoms: effects on the peripheral neuromuscular system with comments on the role of phospholipases A2 in disorders of the CNS and their uses in industry. Toxins (Basel) 2013, 5(12):2533-2571. 10.3390/toxins5122533.
32. Gold B.S., Dart R.C., Barish R.A. Bites of venomous snakes. NEngl J Med 2002, 347(5):347-356. [review].
33. Estes M.L., Ewing-Wilson D., Chou S.M., et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987, 82(3):447-455.
34. Azimian M., Gultekin S.H., Hata J.L., et al. Fatal antimalarial-induced cardiomyopathy: report of 2 cases. JClin Rheumatol 2012, 18(7):363-366.
35. Casado E., Gratacós J., Tolosa C., et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006, 65(3):385-390.
36. Mastaglia F.L., Papadimitriou J.M., Dawkins R.L., et al. Vacuolar myopathy associated with chloroquine, lupus erythematosus and thymoma. Report of a case with unusual mitochondrial changes and lipid accumulation in muscle. JNeurol Sci 1977, 34(3):315-328.
37. Le Quintrec J.S., Le Quintrec J.L. Drug-induced myopathies. Baillieres Clin Rheumatol 1991, 5(1):21-38.
38. Abdel-Hamid H., Oddis C.V., Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve 2008, 38(3):1206-1210.
39. Pulipaka U., Lacomis D., Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. JClin Neuromuscul Dis 2002, 3(3):97-105.
40. Fernando Roth R., Itabashi H., Louie J., et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 1990, 119(5):1223-1225.
41. Alsheikh-Ali A.A., Karas R.H. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 2005, 8(2):95-97.
42. Kuncl R.W., Duncan G., Watson D., et al. Colchicine myopathy and neuropathy. NEngl J Med 1987, 316(25):1562-1568.
43. Kuncl R.W., Cornblath D.R., Avila O., et al. Electrodiagnosis of human colchicine myoneuropathy. Muscle Nerve 1989, 12(5):360-364.
44. Teener J.W. Inflammatory and toxic myopathy. Semin Neurol 2012, 32(5):491-499.
45. Baker S.K., Goodwin S., Sur M., et al. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004, 30(6):799-802.
46. Caglar K., Odabasi Z., Safali M., et al. Colchicine-induced myopathy with myotonia in a patient with chronic renal failure. Clin Neurol Neurosurg 2003, 105(4):274-276.
47. Rutkove S.B., De Girolami U., Preston D.C., et al. Myotonia in colchicine myoneuropathy. Muscle Nerve 1996, 19(7):870-875.
48. Fernandez C., Figarella-Branger D., Alla P., et al. Colchicine myopathy: a vacuolar myopathy with selective type I muscle fiber involvement. An immunohistochemical and electron microscopic study of two cases. Acta Neuropathol 2002, 103(2):100-106.
49. Bradley W.G., Lassman L.P., Pearce G.W., et al. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. JNeurol Sci 1970, 10(2):107-131.
50. Scruggs E.R., Dirks Naylor A.J. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 2008, 82(2):83-88. 10.1159/000134943.
51. Dalakas M.C., Illa I., Pezeshkpour G.H., et al. Mitochondrial myopathy caused by long-term zidovudine therapy. NEngl J Med 1990, 322(16):1098-1105.
52. Robinson-Papp J., Simpson D.M. Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve 2009, 40(6):1043-1053.
53. Simpson D.M., Bender A.N. Human immunodeficiency virus-associated myopathy: analysis of 11 patients. Ann Neurol 1988, 24(1):79-84.
54. Simpson D.M., Slasor P., Dafni U., et al. Analysis of myopathy in a placebo-controlled zidovudine trial. Muscle Nerve 1997, 20(3):382-385.
55. Chalmers A.C., Greco C.M., Miller R.G. Prognosis in AZT myopathy. Neurology 1991, 41(8):1181-1184.
56. Cupler E.J., Danon M.J., Jay C., et al. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol 1995, 90(1):1-6.
57. Feinberg D.M., Spiro A.J., Weidenheim K.M. Distinct light microscopic changes in human immunodeficiency virus-associated nemaline myopathy. Neurology 1998, 50(2):529-531.
58. Johnson R.W., Williams F.M., Kazi S., et al. Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome. Arthritis Rheum 2003, 49(2):172-178.
59. Arnaudo E., Dalakas M., Shanske S., et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991, 337(8740):508-510.
60. Mhiri C., Baudrimont M., Bonne G., et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 1991, 29(6):606-614.
61. Masanés F., Barrientos A., Cebrián M., et al. Clinical, histological and molecular reversibility of zidovudine myopathy. JNeurol Sci 1998, 159(2):226-228.
62. Benbrik E., Chariot P., Bonavaud S., et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. JNeurol Sci 1997, 149(1):19-25.
63. Pedrol E., Masanés F., Fernández-Solá J., et al. Lack of muscle toxicity with didanosine (ddI). Clinical and experimental studies. JNeurol Sci 1996, 138(1-2):42-48.
64. Simpson D.M., Katzenstein D.A., Hughes M.D., et al. Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. AIDS 1998, 12(18):2425-2432.
65. Fernstrom J.D. Effects and side effects associated with the non-nutritional use of tryptophan by humans. JNutr 2012, 142(12):2236S-2244S.
66. Hertzman P.A., Blevins W.L., Mayer J., et al. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. NEngl J Med 1990, 322:869-873.
67. Kamb M.L., Murphy J.J., Jones J.L., et al. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA 1992, 267:77-82.
68. Kaufman L.D., Philen R.M. Tryptophan: current status and future trends for oral administration. Drug Saf 1993, 8:89-98.
69. Kaufman L.D., Gruber B.L., Gregersen P.K. Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome. Lancet 1991, 337:1071-1074.
70. Owens W.E., Bertorini T.E., Holt H.T., et al. Diffuse fasciitis with eosinophilia (shulman syndrome). JClin Neuromuscul Dis 2004, 6(2):99-101.
71. Hertzman P.A., Clauw D.J., Kaufman L.D., et al. The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2 years after onset. Ann Intern Med 1995, 122(11):851-855.
72. Smith B.E., Dyck P.J. Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Neurology 1990, 40(7):1035-1040.
73. Burns S.M., Lange D.J., Jaffe I., et al. Axonal neuropathy in eosinophilia-myalgia syndrome. Muscle Nerve 1994, 17(3):293-298.
74. Donofrio P.D., Stanton C., Miller V.S., et al. Demyelinating polyneuropathy in eosinophilia-myalgia syndrome. Muscle Nerve 1992, 15(7):796-805.
75. Patterson R., Germolec D. Review article toxic oil syndrome: review of immune aspects of the disease. JImmunotoxicol 2005, 2(1):51-58.
76. Chappel R., Willems J. D-penicillamine-induced myositis in rheumatoid arthritis. Clin Rheumatol 1996, 15(1):86-87.
77. Halla J.T., Fallahi S., Koopman W.J. Penicillamine-induced myositis. Observations and unique features in two patients and review of the literature. Am J Med 1984, 77(4):719-722.
78. Watson A.J., Dalbow M.H., Stachura I., et al. Immunologic studies in cimetidine-induced nephropathy and polymyositis. NEngl J Med 1983, 308(3):142-145.
79. Hawkins R.A., Eckhoff P.J., MacCarter D.K., et al. Cimetidine and polymyositis. NEngl J Med 1983, 309(3):187-188.
80. Mitchell G.G., Magnusson A.R., Weiler J.M. Cimetidine-induced cutaneous vasculitis. Am J Med 1983, 75(5):875-876.
81. Lewis C.A., Boheimer N., Rose P., et al. Myopathy after short term administration of procainamide. Br Med J (Clin Res Ed) 1986, 292(6520):593-594.
82. Agius M.A., Zhu S., Fairclough R.H. Antirapsyn antibodies in chronic procainamide-associated myopathy (CPAM). Ann N Y Acad Sci 1998, 841:527-529.
83. Engel J.N., Mellul V.G., Goodman D.B. Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. Am J Med 1986, 81(5):928-930.
84. Dimachkie M.M., Vriesendorp F.J., Heck K.A. Phenytoin-induced dermatomyositis: case report and literature review. Child Neurol 1998, 13(11):577-580.
85. Cirigliano G., Della Rossa A., Tavoni A., et al. Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 1999, 19(1-2):65-67.
86. Hengstman G.J., Vogels O.J., ter Laak H.J., et al. Myositis during long-term interferon-alpha treatment. Neurology 2000, 54(11):2186.
87. Greenberg S.A. Type 1 interferons and myositis. Arthritis Res Ther 2010, 12(Suppl 1):S4. 10.1186/ar2885.
88. Walsh R.J., Kong S.W., Yao Y., et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56(11):3784-3792.
89. Adenis A., Bouché O., Bertucci F., et al. Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. JMed Oncol 2012, 29(4):3003-3008. 10.1007/s12032-012-0204-1.
90. Srinivasan J., Wu C.J., Amato A.A. Inflammatory myopathy associated with imatinib mesylate therapy. Clin Neuromuscul Dis 2004, 5(3):119-121.
91. Bowyer S.L., LaMothe M.P., Hollister J.R. Steroid myopathy: incidence and detection in a population with asthma. JAllergy Clin Immunol 1985, 76:234-242.
92. Hollister J.R. The untoward effects of steroid treatment on the musculoskeletal system and what to do about them. JAsthma 1992, 29:363-368.
93. Khaleeli A.A., Edwards R.H., Gohil K., et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol 1983, 18:155-166.
94. Kissel J.T., Mendell J.R. The endocrine myopathies. Handbook of clinical neurology vol. 18, no. 62 myopathies 1992, 527-551. Elsevier Science Publishers BV, Amsterdam. L.P. Rowland, S. Dimauro (Eds.).
95. Faludi G., Gotlieb J., Meyers J. Factors influencing the development of steroid-induced myopathies. Ann N Y Acad Sci 1966, 138(1):62-72.
96. Buchthal F. Electrophysiological abnormalities in metabolic myopathies and neuropathies. Acta Neurol Scand 1970, 46(Suppl 43):129-176.
97. Srinivasan J., Amato A.A. Myopathies. Phys Med Rehabil Clin N Am 2003, 14(2):403-434.
98. Dimachkie M.M., Barohn R.J. Idiopathic inflammatory myopathies. Semin Neurol 2012, 32(3):227-236. 10.1055/s-0032-1329201.
99. Haan J., Hollander J.M., van Duinen S.G., et al. Reversible severe myopathy during treatment with finasteride. Muscle Nerve 1997, 20(4):502-504.
100. Thyagarajan D., Day B.J., Wodak J., et al. Emetine myopathy in a patient with an eating disorder. Med J Aust 1993, 159(11-12):757-760.
101. Dresser L.P., Massey E.W., Johnson E.E., et al. Ipecac myopathy and cardiomyopathy. Neurol Neurosurg Psychiatry 1993, 56(5):560-562.
102. Lacomis D. Case of the month. June 1996-anorexia nervosa. Brain Pathol 1996, 6(4):535-536.
103. Kuntzer T., Bogousslavsky J., Deruaz J.P., et al. Reversible emetine-induced myopathy with ECG abnormalities: a toxic myopathy. JNeurol 1989, 236(4):246-248.
104. Latronico N., Tomelleri G., Filosto M. Critical illness myopathy. Curr Opin Rheumatol 2012, 24(6):616-622.
105. Dimachkie MM. Critical illness myopathy and polyneuropathy. Medlink, 2013.
106. Hirano M., Ott B.R., Raps E.C., et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992, 42:2082-2087.
107. MacFarlane I., Rosenthal F. Severe myopathy after status asthmaticus. Lancet 1977, 2:615.
108. Lacomis D., Chad D.A., Aronin N., et al. The myopathy of Cushing's syndrome. Muscle Nerve 1993, 16:880-881.
109. Lacomis D., Giuliani M.J., Van Cott A., et al. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996, 40:645-654.
110. Hermans G., De Jonghe B., Bruyninckx F., et al. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev 2009, (1). CD006832.
111. Hough C.L., Steinberg K.P., Taylor Thompson B., et al. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009, 35(1):63-68.
112. Barohn R.J., Jackson C.E., Rogers S.J., et al. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids. Muscle Nerve 1994, 17:647-654.
113. Kaminski H.J., Ruff R.L. Endocrine myopathies (hyper- and hypofunction of adrenal, thyroid, pituitary, and parathyroid glands and iatrogenic corticosteroid myopathy). Myology 1994, 1726-1753. McGraw-Hill, New York. 2nd edition. A.G. Engel, C. Franzini-Armstrong (Eds.).
114. Clark D.W., Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?. Eur J Clin Pharmacol 2006, 62(6):473-479.
115. Garrote F.J., Lacambra C., del Ser T., et al. Subacute myopathy during omeprazole therapy. Lancet 1992, 340(8820):672.
116. Faucheux J.M., Tournebize P., Viguier A., et al. Neuromyopathy secondary to omeprazole treatment. Muscle Nerve 1998, 21(2):261-262.
117. Chroni E., Monastirli A., Tsambaos D. Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf 2010, 33(1):25-34.
118. Sarifakioglu E., Onur O., Kart H., et al. Acute myopathy and acne fulminans triggered by isotretinoin therapy. Eur J Dermatol 2011, 21(5):794-795.
119. Klingler W., Heiderich S., Girard T., et al. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study. Orphanet J Rare Dis 2014, 9(1):8. 10.1186/1750-1172-9-8.
120. Visoiu M., Young M.C., Wieland K., et al. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg 2014, 118(2):388-396.
121. Schuster F., Johannsen S., Roewer N. Aminimal-invasive metabolic test detects malignant hyperthermia susceptibility in a patient after sevoflurane-induced metabolic crisis. Case Rep Anesthesiol 2013, 2013:953859.
122. Schuster F., Johannsen S., Schneiderbanger D., et al. Evaluation of suspected malignant hyperthermia events during anesthesia. BMC Anesthesiol 2013, 13(1):24. 10.1186/1471-2253-13-24.
123. Nelson P., Litman R.S. Malignant hyperthermia in children: an analysis of the north american malignant hyperthermia registry. Anesth Analg 2014, 118(2):369-374.
124. Lang C.H., Frost R.A., Summer A.D., et al. Molecular mechanisms responsible for alcohol-induced myopathy in skeletal muscle and heart. Int J Biochem Cell Biol 2005, 37(10):2180-2195.
125. Preedy V.R., Ohlendieck K., Adachi J., et al. The importance of alcohol-induced muscle disease. JMuscle Res Cell Motil 2003, 24(1):55-63.